Koch G G, Tangen C M, Jung J W, Amara I A
Department of Biostatistics, University of North Carolina, Chapel Hill, USA.
Stat Med. 1998;17(15-16):1863-92. doi: 10.1002/(sici)1097-0258(19980815/30)17:15/16<1863::aid-sim989>3.0.co;2-m.
Analysis of covariance is an effective method for addressing two considerations for randomized clinical trials. One is reduction of variance for estimates of treatment effects and thereby the production of narrower confidence intervals and more powerful statistical tests. The other is the clarification of the magnitude of treatment effects through adjustment of corresponding estimates for any random imbalances between the treatment groups with respect to the covariables. The statistical basis of covariance analysis can be either non-parametric, with reliance only on the randomization in the study design, or parametric through a statistical model for a postulated sampling process. For non-parametric methods, there are no formal assumptions for how a response variable is related to the covariables, but strong correlation between response and covariables is necessary for variance reduction. Computations for these methods are straightforward through the application of weighted least squares to fit linear models to the differences between treatment groups for the means of the response variable and the covariables jointly with a specification that has null values for the differences that correspond to the covariables. Moreover, such analysis is similarly applicable to dichotomous indicators, ranks or integers for ordered categories, and continuous measurements. Since non-parametric covariance analysis can have many forms, the ones which are planned for a clinical trial need careful specification in its protocol. A limitation of non-parametric analysis is that it does not directly address the magnitude of treatment effects within subgroups based on the covariables or the homogeneity of such effects. For this purpose, a statistical model is needed. When the response criterion is dichotomous or has ordered categories, such a model may have a non-linear nature which determines how covariance adjustment modifies results for treatment effects. Insight concerning such modifications can be gained through their evaluation relative to non-parametric counterparts. Such evaluation usually indicates that alternative ways to compare treatments for a response criterion with adjustment for a set of covariables mutually support the same conclusion about the strength of treatment effects. This robustness is noteworthy since the alternative methods for covariance analysis have substantially different rationales and assumptions. Since findings can differ in important ways across alternative choices for covariables (as opposed to methods for covariance adjustment), the critical consideration for studies with covariance analyses planned as the primary method for comparing treatments is the specification of the covariables in the protocol (or in an amendment or formal plan prior to any unmasking of the study.
协方差分析是一种用于处理随机临床试验中两个问题的有效方法。一是减少治疗效果估计值的方差,从而产生更窄的置信区间和更强大的统计检验。另一个是通过调整治疗组之间在协变量方面的任何随机不平衡的相应估计值,来阐明治疗效果的大小。协方差分析的统计基础可以是非参数的,仅依赖于研究设计中的随机化,也可以是参数的,通过假设抽样过程的统计模型。对于非参数方法,对于响应变量与协变量之间的关系没有正式假设,但响应与协变量之间的强相关性对于方差减少是必要的。这些方法的计算通过应用加权最小二乘法将线性模型拟合到治疗组之间响应变量和协变量均值的差异上,并且对于与协变量对应的差异具有零值的规范,计算很简单。此外,这种分析同样适用于二分指标、有序类别中的秩或整数以及连续测量。由于非参数协方差分析可以有多种形式,计划用于临床试验的形式需要在其方案中仔细规定。非参数分析的一个局限性是它不能直接解决基于协变量的亚组内治疗效果的大小或此类效果的同质性问题。为此,需要一个统计模型。当响应标准是二分的或有有序类别时,这样的模型可能具有非线性性质,它决定了协方差调整如何修改治疗效果的结果。通过相对于非参数对应物的评估可以获得关于此类修改的见解。这种评估通常表明,在对一组协变量进行调整的情况下,比较响应标准的治疗方法的替代方法相互支持关于治疗效果强度的相同结论。这种稳健性是值得注意的,因为协方差分析的替代方法有实质上不同的原理和假设。由于对于协变量的替代选择(与协方差调整方法相反),研究结果可能在重要方面有所不同,对于计划将协方差分析作为比较治疗的主要方法的研究,关键考虑因素是在方案(或在研究揭盲之前的修正案或正式计划)中协变量的规定。